Skip to main content

Table 2 PSMA-ligand PET results and radiotherapy of metastases

From: Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

PSMA-ligand PET results

N (%)

Number of PSMA-ligand positive lesions

185 (100

Total number of LNs

128 (69.2)

 Iliac LNs

67 (36.2)

 Obturator LNs

6 (3.2)

 Perirectal LNs

4 (2.2)

 Periaortic/interaortocaval LNs

51 (27.6)

Total number of bone metastases

45 (24.3)

 Pelvic bone

24 (13.0)

 Spinal bone

10 (5.4)

 Other

11 (5.9)

Number of visceral metastases

12 (6.5)

Concurrent ADT at radiotherapy

13 (16.7)

Radiotherapy of metastases

N (%)

Radiotherapy of LNs

128 (100)

CF-RT

95 (74.2)

SBRT

5 (3.9)

CF-RT plus SBRT

15 (11.7)

CF-RT with SIB

13 (10.2)

Median dose, EQD2/1.5 Gy (range)

50.9 (50.0–76.1)

 

N (%)

Radiotherapy of bone metastases

45 (100%)

CF-RT

26 (57.8)

SBRT

15 (33.3)

CF-RT plus SBRT

0 (0)

CF-RT with SIB

4 (8.9)

Median dose, EQD2/1.5 Gy (range)

51.4 (46.4–108.8

 

N (%)

Radiotherapy of visceral metastases

12 (100)

CF-RT

8 (66.7)

SBRT

4 (33.3)

CF-RT plus SBRT

0

CF-RT with SIB

0

Median dose, EQD2/1.5 Gy (range)

64.7 (57.8–85.0)

  1. ADT androgen deprivation therapy, CF-RT conventionally fractionated radiotherapy type, Gy Gray, LNs lymph node metastases, PCa prostate cancer, PSMA-PET prostate-specific membrane antigen positron emission tomography, PSA prostate-specific antigen, RP radical prostatectomy, sRT salvage radiotherapy, SBRT stereotactic body radiation therapy, SIB simultaneous integrated boost